Spots Global Cancer Trial Database for Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields
Official Title: The PROTECT Study: A Phase II, Open-Label Trial of PROphylactic Skin Toxicity ThErapy With Clindamycin and Triamcinolone in Glioblastoma Patients Treated With Tumor Treating Fields
Study ID: NCT04469075
Study Description
Brief Summary: The participants are being treated with Tumor Treating Fields (TTFields) for malignant glioma, and this type of treatment may cause skin-related side effects. This study will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Northwestern University, Evanston, Illinois, United States
Tufts Medical Center, Boston, Massachusetts, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Hackensack Meridian Health, Hackensack, New Jersey, United States
Memorial Sloan Kettering Cancer Center Suffolk - Hauppauge (All Protocol Activities), Hauppauge, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Columbia University, New York, New York, United States
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Contact Details
Name: Alina Markova, MD
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
